StockData
Medpace Holdings, Inc. logo

Medpace Holdings, Inc. (MEDP) stock

MEDPNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 22, 2026Score 14/3042% above fair value
$653.09+4.89 (+0.75%)

Close on Nov 17, 2026Market cap $18.27BP/E 36.2Yield –

Medpace r&d expenses

Research and development expenses are spending on new products and technology.

No r&d expenses figures for Medpace

Medpace has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Medpace figures

See a number that looks wrong?